Gastric Cancer (Oncology) - Drugs In Development, 2021

August 2021 | 3373 pages | ID: G618D5D76D74EN
Global Markets Direct

Abstracts

Gastric Cancer (Oncology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Drugs In Development, 2021, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 23, 180, 223, 5, 26, 202, 42 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 12, 10, 1, 1, 9 and 3 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Gastric Cancer - Overview
Gastric Cancer - Therapeutics Development
Gastric Cancer - Therapeutics Assessment
Gastric Cancer - Companies Involved in Therapeutics Development
Gastric Cancer - Drug Profiles
Gastric Cancer - Dormant Projects
Gastric Cancer - Discontinued Products
Gastric Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Gastric Cancer, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Gastric Cancer - Pipeline by 3SBio Inc, 2021
Gastric Cancer - Pipeline by AbbVie Inc, 2021
Gastric Cancer - Pipeline by Abclon Inc, 2021
Gastric Cancer - Pipeline by Abion Inc, 2021
Gastric Cancer - Pipeline by ABL Bio Inc, 2021
Gastric Cancer - Pipeline by Abpro Corp, 2021
Gastric Cancer - Pipeline by AbTis Co Ltd, 2021
Gastric Cancer - Pipeline by Accurus Biosciences Inc, 2021
Gastric Cancer - Pipeline by Acrotech Biopharma LLC, 2021
Gastric Cancer - Pipeline by AD Pharmaceuticals Co Ltd, 2021
Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, 2021
Gastric Cancer - Pipeline by ADC Therapeutics SA, 2021
Gastric Cancer - Pipeline by Advenchen Laboratories LLC, 2021
Gastric Cancer - Pipeline by Affimed GmbH, 2021
Gastric Cancer - Pipeline by AffyImmune Therapeutics Inc, 2021
Gastric Cancer - Pipeline by Agenus Inc, 2021
Gastric Cancer - Pipeline by AIMM Therapeutics BV, 2021
Gastric Cancer - Pipeline by Akeso Inc, 2021
Gastric Cancer - Pipeline by Alkermes Plc, 2021
Gastric Cancer - Pipeline by Alligator Bioscience AB, 2021
Gastric Cancer - Pipeline by Alphamab Oncology, 2021
Gastric Cancer - Pipeline by Alteogen Inc, 2021
Gastric Cancer - Pipeline by AltruBio Inc, 2021
Gastric Cancer - Pipeline by ALX Oncology Holdings Inc, 2021
Gastric Cancer - Pipeline by Ambrx Biopharma Inc, 2021
Gastric Cancer - Pipeline by amcure GmbH, 2021
Gastric Cancer - Pipeline by Amgen Inc, 2021
Gastric Cancer - Pipeline by Andes Biotechnologies, 2021
Gastric Cancer - Pipeline by Anew Oncology Inc, 2021
Gastric Cancer - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, 2021
Gastric Cancer - Pipeline by Antikor Biopharma Ltd, 2021
Gastric Cancer - Pipeline by Apollomics Inc, 2021
Gastric Cancer - Pipeline by Apotex Inc, 2021
Gastric Cancer - Pipeline by Aprea Therapeutics Inc, 2021
Gastric Cancer - Pipeline by Arbele Ltd, 2021
Gastric Cancer - Pipeline by Arcus Biosciences Inc, 2021
Gastric Cancer - Pipeline by Argonaut Therapeutics Ltd, 2021
Gastric Cancer - Pipeline by Arog Pharmaceuticals Inc, 2021
Gastric Cancer - Pipeline by Arromax Pharmatech Co Ltd, 2021
Gastric Cancer - Pipeline by Aryogen Pharmed, 2021
Gastric Cancer - Pipeline by Immunicum AB, 2021
Gastric Cancer - Pipeline by Immunisbio Co Ltd, 2021
Gastric Cancer - Pipeline by ImmunityBio Inc, 2021
Gastric Cancer - Pipeline by Immunocore Holdings Plc, 2021
Gastric Cancer - Pipeline by Immunomet Therapeutics Inc, 2021
Gastric Cancer - Pipeline by Immunomic Therapeutics Inc, 2021
Gastric Cancer - Pipeline by Immunotech Biopharm Ltd, 2021
Gastric Cancer - Pipeline by Imugene Ltd, 2021
Gastric Cancer - Pipeline by Incyte Corp, 2021
Gastric Cancer - Pipeline by Inhibrx Inc, 2021
Gastric Cancer - Pipeline by Inner Mongolia Qite Biotechnology (Group) Co Ltd, 2021
Gastric Cancer - Pipeline by Innovative Cellular Therapeutics Co Ltd, 2021
Gastric Cancer - Pipeline by Innovent Biologics Inc, 2021
Gastric Cancer - Pipeline by Inovio Pharmaceuticals Inc, 2021
Gastric Cancer - Pipeline by Intocell Inc, 2021
Gastric Cancer - Pipeline by Intra-Immusg Pvt Ltd, 2021
Gastric Cancer - Pipeline by InxMed Shanghai Co Ltd, 2021
Gastric Cancer - Pipeline by Ipsen SA, 2021
Gastric Cancer - Pipeline by Istari Oncology Inc, 2021
Gastric Cancer - Pipeline by Ithax Pharmaceuticals Inc, 2021
Gastric Cancer - Pipeline by JenKem Technology Co Ltd, 2021
Gastric Cancer - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2021
Gastric Cancer - Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, 2021
Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, 2021
Gastric Cancer - Pipeline by Jina Pharmaceuticals Inc, 2021
Gastric Cancer - Pipeline by Jiuzhitang Co Ltd, 2021
Gastric Cancer - Pipeline by Johnson & Johnson, 2021
Gastric Cancer - Pipeline by Joint Biosciences Ltd, 2021
Gastric Cancer - Pipeline by Jounce Therapeutics Inc, 2021
Gastric Cancer - Pipeline by JW Pharmaceutical Corp, 2021
Gastric Cancer - Pipeline by Karyo Biologics LLC, 2021
Gastric Cancer - Pipeline by Karyopharm Therapeutics Inc, 2021
Gastric Cancer - Pipeline by KeyMed Biosciences Inc, 2021
Gastric Cancer - Pipeline by Keythera Pharmaceuticals Co Ltd, 2021
Gastric Cancer - Pipeline by Kintor Pharmaceutical Ltd, 2021
Gastric Cancer - Pipeline by KLUS Pharma Inc, 2021
Gastric Cancer - Pipeline by Komipharm International Co Ltd, 2021
Gastric Cancer - Pipeline by Kringle Pharma Inc, 2021
Gastric Cancer - Pipeline by Kupffer Biotherapeutics Inc, 2021
Gastric Cancer - Pipeline by Kymab Ltd, 2021
Gastric Cancer - Pipeline by Kyowa Kirin Co Ltd, 2021
Gastric Cancer - Pipeline by LaNova Medicines Ltd, 2021
Gastric Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, 2021
Gastric Cancer - Pipeline by Lead Discovery Center GmbH, 2021
Gastric Cancer - Pipeline by Leap Therapeutics Inc, 2021
Gastric Cancer - Pipeline by Turnstone Biologics Inc, 2021
Gastric Cancer - Pipeline by Tvardi Therapeutics Inc, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gastric Cancer, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021